Carlos Fernandez-Lozano

This paper identifies Cx43 as a target that enhances CDK4/6 inhibitor efficacy and promotes elimination of therapy-induced senescent tumor cells through senolytic agents.

PRECISION uses a heterogeneous graph neural network with biological knowledge to identify drug repurposing candidates in TNBC, showing associations between predicted drug sensitivity and survival in multiple cohorts.

This study shows that Cx43 enhances the effectiveness of BRAF/MEKi by reducing DNA repair, leading to increased DNA damage and cellular senescence, and proposes a novel therapeutic approach using sEVs.

This study develops a 37-gene prognostic signature for colon cancer and identifies a subgroup sensitive to tubulin inhibitors, with potential for drug repurposing.

The paper presents a large-scale cancer pharmacogenomic screen with 11,576 experiments on 910 drug combinations across 85 cancer cell lines, enabling crowd-sourced prediction of synergistic drug pairs and biomarkers.